GenoMed CEO at StoneBridge Senior Living


David W. Moskowitz MD
CEO, GenoMed
Tel. 314-983-9933

Ms. Delicia T. Stephens
StoneBridge Maryland Heights
2963 Doddridge Avenue
Maryland Heights, MO 63043
Cell: 314-452-4886
Ofc: 314-743-3862
Fax: 314-222-5107

ST. LOUIS—January 13, 2010—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced that its CEO and Chief Medical Officer, David Moskowitz MD, will be giving a seminar on how to prevent dialysis at StoneBridge Maryland Heights, a skilled nursing and rehabilitation center on Thursday, January 14, 2010 from 1:30 pm to 2:30 pm.

Dr. Moskowitz said, “We believe that we’ve found the major aging gene, and that we can give people 5 extra years of life at their current level of quality.”

Dr. Moskowitz continued, “My paper showing how to prevent at least 90% of kidney failure was published in September, 2002. People over the age of 80 are the fastest-growing segment of the population going on dialysis.”

Dr. Moskowitz ended by saying, “My goal is to provide information on how to keep residents at StoneBridge and those in the community off dialysis. I’m delighted to share such exciting information with a wonderful community like StoneBridge.”

About StoneBridge Maryland Heights

With over 220 residents, StoneBridge Maryland Heights offers skilled care, rehabilitative care, and memory care all on one campus. It is one of nine communities owned and operated by Eldercare Management Services ( in Missouri. The StoneBridge Communities are pioneers in bringing the latest research and technology together to create the highest quality patient care.

About GenoMed (

GenoMed was founded in 2001 by Dr. David Moskowitz, a kidney specialist. The company recently began a “Dialysis-Free in 5” campaign: it will gladly work with any community in the world that wants to eliminate at least 90% of dialysis within 5 years. GenoMed is working to make St. Louis dialysis-free by 2015.

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.